Basilea Pharmaceutica AG

Research Basilea Pharmaceutica AG (BSLN) on Bullrun: market cap CHF 629.97M, P/E 16.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBSLN
• ExchangeSW
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCHF
• Market capCHF 629.97M
• P/E16.2
• Financial periodFY2025
• RevenueCHF 232.38M
• Revenue growth11.4%
• Net incomeCHF 40.24M
• Free cash flowCHF 59.23M
• Gross margin83.1%

Valuation Snapshot

latest market cap is CHF 629.97M; P/E is 16.2.

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis;

Frequently asked questions

What is Basilea Pharmaceutica AG's market cap?

Basilea Pharmaceutica AG's market capitalization is CHF 629.97M.

What is Basilea Pharmaceutica AG's P/E ratio?

Basilea Pharmaceutica AG's price-to-earnings (P/E) ratio is 16.2.

What does Basilea Pharmaceutica AG do?

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.